Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab and IO102-103 in SCCHN
NCT05977907Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PD-L1/IDO peptide vaccine, pembrolizumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Dec 2023; status: active, not recruiting.
02
Drugs
PD-L1/IDO peptide vaccinepembrolizumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05977907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05977907.